<DOC>
	<DOC>NCT02433795</DOC>
	<brief_summary>This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).</brief_summary>
	<brief_title>Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)</brief_title>
	<detailed_description>Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of bendamustine and rituximab in patients with MZBCL who has relapsed or progressive to prior chemotherapy or chemo-radiotherapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1. Histologically confirmed CD20positive nodal or extranodal MZBCL 2. MZBCL patients who relapsed or progressed: At least one and a maximum of four prior lines of chemotherapy During or after the last chemotherapy or radiotherapy or Without progression within 6 months of the last dose of rituximabbased regimen 3. Patients age â‰¥ 18 years 4. ECOG PS 02 5. At least one bidimensionally measurable disease 6. Adequate hematologic, renal, and hepatic functions 7. Women of childbearing potential should use two appropriate methods of contraception during the study 8. Written informed consent 1. Not all of the above inclusion criteria are met. 2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks 3. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of &lt; 20mg/day for indications other than lymphomas 4. Evidence of CNS involvement by lymphomas 5. Active HBV/HCV infections, known HIV infection 6. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized nonmelanoma skin cancer, or small differentiated thyroid cancer 7. Serious concurrent disease: 8. Patients who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Marginal zone B-cell lymphoma</keyword>
	<keyword>bendamustine plus rituximab</keyword>
</DOC>